Get to Know R-Crio

We believe that taking action to improve our quality of life is no longer a distant dream but reality. Therefore, R•Crio is driven by a single goal: to use technology to improve life, with responsibility and commitment.

A little seed planted today may blossom into a fulfilling and healthy life. That’s why we care for the new generations with the same affection and dedication as their parents. We are not only thinking about the present, but about the entire life trajectory of a child.

To infinity and beyond

We have the mission of enabling health and quality of life through stem cell storage and knowledge of the individual genetic profile of every family who believes and trusts in our work.

Unsurprisingly, R•Crio has eyes in the future! That’s what motivates us to contribute to the advancement of personalized medicine and to work hard for the wellbeing and health of all. Therefore, we have not a dream, but a vision to be present to thousands of families, deciphering and preserving what is essential to life.

Just the beginning of a long journey

We have a history of over 10 years of research in the medical field and heavy investment in technology and infrastructure. Follow our journey:

  • 2005

    Biomaterials research for bone regeneration.

  • 2006

    Reprogrammed cells

    Shinya Yamanaka and his team at the University of Kyoto, in Japan, discover how to make adult cells pluripotent again. His team reprograms adult cells by inserting and expressing four critical genes, thereby generating induced pluripotent stem (iPS) cells.

  • 2007

    Research in the development of a stem cell scaffold for bone regeneration.

  • 2007


    Sir Martin J. Evans shares the Nobel Prize in Physiology or Medicine with Mario Capecchi and Oliver Smithies for their work in genetics and embryonic stem cells.

  • 2009

    Collaboration with the University of São Paulo for research on dental stem cells and the use of hydroxyapatite.

  • 2010


    A patient with spinal cord injury became the first person to receive a medical treatment using human embryonic stem cells. It was part of a trial conducted by the Geron Corporation, a pioneer company in embryonic stem cells therapy.

  • 2011

    R-Crio begins the development of its business plan.

  • 2012

    Finish documenting the operations process.

  • 2012


    Yamanaka shares a Nobel Prize with John Gurdon, of the University of Cambridge, for his work with iPS cells.

  • 2013

    Filing of patent application and first round of investment

  • 2014

    R-Crio starts operating.

  • 2014


    The RIKEN Institute, in Japan, enrolls patients for a clinical trial using iPS cells, aiming at treating age-related blindness.

  • 2015

    Certification by Anvisa.

High-Quality Infrastructure

R-Crio possesses a highly qualified team of professionals with masters, doctorate and post-doctorate degrees by leading universities and research centers, from the lab up to the presidency of the company. That’s what brought us here and what takes us ever further ahead!

Patent-protected process

R•Crio possesses cutting edge infrastructure, a unique, patented cell processing technology certified by Anvisa as well as a processing area classified as ISO 7.

The only company collecting exclusively dental pulp cells

Since the very beginning we sought for quality and innovation. We are the only company to exclusively collect stem cells from the pulp of baby teeth.

Digital Tracking System for Cryopreservation

We have a digital tracking system that guarantees the traceability of the entire process, from tooth extraction to cryopreservation. For the execution of every process, we conduct a homogeneous and high-quality work, every time.